FrancophonIA/ELRC3.0 huggingface dataset:
English: After considering the grounds for this request, the CHMP re-examined the initial opinion, and confirmed the refusal of the marketing authorisation on 22 September 2014.
Latvian: Izvērtējusi šīs prasības pamatojumu, CHMP vēlreiz pārskatīja savu sākotnējo atzinumu un 2014. gada 22. septembrī apstiprināja reģistrācijas apliecību izsniegšanas atteikumu.
English: On 22 May 2014, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of a change to the marketing authorisation for the medicinal product Avastin.
Latvian: Cilvēkiem paredzēto zāļu komiteja (CHMP) 2014. gada 22. maijā pieņēma negatīvu atzinumu, iesakot atteikt reģistrācijas apliecības izmaiņas zālēm Avastin.
English: The company informed the CHMP that there are no consequences for patients with glioblastoma receiving Avastin in clinical trials: patients will continue to receive Avastin in the on-going and future clinical trials.
Latvian: Uzņēmums informēja CHMP, ka pacientiem, kas klīniskajos pētījumos saņem Avastin, netiks radītas sekas: pašreiz notiekošajos un nākotnes klīniskajos pētījumos pacienti arī turpmāk saņems Avastin.
English: There are no consequences on the use of Avastin in its authorised indications.
Latvian: Avastin lietošanā apstiprināto indikāciju gadījumos seku nav.
English: Avastin was also expected to be used to treat adult patients with newly diagnosed glioblastoma in combination with radiotherapy (treatment with radiation) and temozolomide (another cancer medicine).
Latvian: Avastin bija paredzēts lietot arī pieaugušiem pacientiem ar pirmreizēji diagnosticētu glioblastomu kombinācijā ar staru terapiju (terapija ar starojumu) un temozolamīdu (citas pretvēža zāles).
English: What were the CHMP's main concerns that led to the refusal of the change to the marketing authorisation?
Latvian: Kādas bija CHMP galvenās bažas, kuru dēļ tika pieņemts reģistrācijas apliecības izmaiņu atteikums?
English: Avastin is a cancer medicine that contains the active substance bevacizumab.
Latvian: Avastin ir pretvēža zāles, kas satur aktīvo vielu bevacizumabu.
English: It is available as a concentrate that is made up into a solution for infusion (drip into a vein).
Latvian: Tās ir pieejamas kā koncentrāts infūziju šķīduma pagatavošanai, ko ievada (pilienveidā) vēnā.
English: During the re-examination, the CHMP looked again at the data from the company and confirmed its opinion that the benefits of Avastin had not been sufficiently demonstrated in newly diagnosed glioblastoma.
Latvian: Atkārtotās pārskatīšanas laikā CHMP apskatīja uzņēmuma datus un apstiprināja savu viedokli, ka pacienta ieguvums, lietojot Avastin pirmreizēji diagnosticētas glioblastomas ārstēšanā, nav pietiekami pierādīts.
English: At the time of the initial recommendation the CHMP noted that the effectiveness of Avastin in combination with radiotherapy and temozolomide had not been sufficiently demonstrated.
Latvian: Sākotnējās rekomendācijas laikā CHMP uzskatīja, ka nav pietiekami pierādīta Avastin iedarbība kombinācijā ar staru terapiju un temozolomīdu.
English: Therefore, at that point in time, the CHMP was of the opinion that the benefits of Avastin in the treatment of newly diagnosed glioblastoma did not outweigh its risks.
Latvian: Tādēļ tobrīd CHMP uzskatīja, ka pacienta ieguvums, lietojot Avastin pirmreizēji diagnosticētas glioblastomas ārstēšanā, nepārsniedz šo zāļu radīto risku.
English: Refusal of a change to the marketing authorisation for Avastin (bevacizumab)
Latvian: Avastin (bevacizumaba) reģistrācijas apliecības izmaiņu atteikums
English: What was Avastin expected to be used for?
Latvian: Kādam nolūkam bija paredzēts lietot Avastin?
English: The active substance in Avastin, bevacizumab, is a monoclonal antibody (a type of protein), that has been designed to recognise and attach to vascular endothelial growth factor (VEGF), a protein that
Latvian: Avastin aktīvā viela bevacizumabs ir monoklonāla antiviela (olbaltumvielas veids), kas izveidota, lai atpazītu vaskulārā endotēlija augšanas faktoru (VEGF) - proteīnu, kas cirkulē asinīs un stimulē asinsvadu augšanu-, un saistītos ar to.
English: Therefore, the CHMP maintained its previous recommendation that the change to the marketing authorisation be refused.
Latvian: Tādēļ CHMP saglabāja iepriekšējo ieteikumu atteikt izmaiņas reģistrācijas apliecībā.
English: In the study, patients received Avastin or placebo (a dummy treatment) in addition to treatment with radiotherapy and temozolomide.
Latvian: Pētījumā papildus staru terapijai un temozolomīdam pacienti saņēma Avastin vai placebo (neīstu ārstēšanas līdzekli).
English: How is Avastin expected to work?
Latvian: Kāda ir paredzamā Avastin iedarbība?
English: By attaching to VEGF, Avastin stops cancer cells from developing their own blood supply and starves them of oxygen and nutrients, helping to slow down the growth of the cancer.
Latvian: nevar izveidot savu asinsapgādes sistēmu un nesaņem skābekli un barības vielas, kas savukārt palīdz palēnināt audzēja augšanu.
English: --1 Porcine circovirus type 2 ORF2 subunit antigen ≥4.5 log2 ELISA units* * Antibody titre obtained according to the in vivo potency test in chickens
Latvian: --1 2. tipa cūku cirkovīrusa ORF2 subvienības antigēns ≥4,5 log2 ELISA vienības*
English: MA (EU) number
Latvian: ES reģistrācijas numurs
English: “Recent” here means between 12 hours and 10 days.
Latvian: “Nesen” šeit noz m laiku starp 12 stund m un 10 dien m.
English: In addition:
Latvian: Bez tam:
English: The mean duration of follow-up was nearly two years.
Latvian: Vid jais r d t ju dokument šanas periods bija aptuveni divus gadus ilgs.
English: Laboratório Normal-Produtos Farmacêuticos, Lda Rua do Centro Empresarial, Edificio 8 Quinta da Beloura
Latvian: Laboratório Normal-Produtos Farmacêuticos, Lda Rua do Centro Empresarial,
English: • if you have recently undergone kidney transplantation (received a new kidney).
Latvian: • Ja Jums nesen bijusi nieru transplant cija (J
English: • if you suffer from aldosteronism.
Latvian: s ciešat no aldosteronisma.
English: • to treat symptomatic heart failure in adult patients.
Latvian: • simptom tiskas sirds mazsp jas rst šanai pieaugušiem pacientiem.
English: In heart failure patients:
Latvian: Sirds mazsp jas pacientiem:
English: • to treat adult patients after a recent heart attack (myocardial infarction).
Latvian: • pieaugušu pacientu, kuri nesen p rcietuši sirdsl kmi (miokarda infarktu) rst šanai.
English: • if you have severe heart disease other than heart failure or heart attack.
Latvian: • Ja Jums ir cita smaga sirds slimba, izemot sirds mazsp ju vai miokarda infarktu.
English: If you have accidentally taken too many tablets, contact your doctor, pharmacist, or hospital.
Latvian: Ja esat nejauši ie mis vairk Diovan tabletes nek noteikts, sazinieties ar savu rstu, farmaceitu vai klniku.
English: If symptomatic hypotension or renal dysfunction occur, consideration should be given to a dose reduction.
Latvian: Ja tiek nov rota simptom tiska hipotensija vai nieru disfunkcija, j apsver devas samazin šana.
English: The addition of a diuretic such as hydrochlorothiazide will decrease blood pressure even further in these patients.
Latvian: Diur tiku, t.i. hidrohlorotiaz da pievienošana pat veicin s asinsspiediena samazin šanu šiem pacientiem.
English: The study report will be finalized by Q4 2010.
Latvian: P t juma zi ojums tiks pabeigts l dz 2010. gada ceturtajam ceturksnim.
English: All-cause mortality was similar in the valsartan (19.9%), captopril (19.5%), and valsartan + captopril (19.3%) groups.
Latvian: Visu c lo u izrais ta mirst ba bija l dz ga valsart na grup (19,9%), kaptoprila (19,5%) un valsart na + kaptoprila grup (19,3%).
English: Adult patients with high blood pressure: The usual dose is 80 mg daily.
Latvian: Pieaugušie pacienti ar augstu asinsspiedienu: Parast deva ir 80 mg dien .
English: You obtain the 20 mg dose by dividing the 40 mg tablet.
Latvian: s ieg siet 20 mg devu, sadalot uz pus m 40 mg tableti.
English: Combining valsartan with captopril did not add further benefit over captopril alone.
Latvian: Kombin jot valsart nu ar kaptoprilu, netika pievienots papildus ieguvums, sal dzinot ar kaptoprilu vienu pašu.
English: Valsartan may be administered with other heart failure therapies.
Latvian: Valsart nu var lietot kop ar citu sirds mazsp jas rst šanas medikamentozo terapiju.
English: • Restart the cycle of PSUR submission for Diovan as follows: o Six-monthly PSURs until two full years of experience with the paediatric indication in the EU has been gained o Yearly PSURs for the following two years o Thereafter submission at 3-yearly intervals The PSURs should focus on the use in the paediatric population.
Latvian: • Diovan periodiski atjaunojamo droš bas zi ojumu (PADZ) iesniegšanas cikls j ats k š di: o PADZ reizi sešos m nešos, l dz ieg ti divi pilni pieredzes gadi attiec b uz pediatrijas popul ciju ES; o PADZ reizi gad turpm kos divus gadus; o p c tam ziojums iesniedzams reizi trs gados.
English: The primary benefit was a 27.5% (95% CI: 17 to 37%) reduction in risk for time to first heart failure hospitalisation (13.9% vs. 18.5%).
Latvian: Prim rais ieguvums bija 27,5% (95% CI: 17 l dz 37%) riskant laika perioda l dz pirmajai hospitaliz cijas epizodei samazin šan (13,9% pret 18,5%).
English: The combination with ACE inhibitors is not recommended (see sections 4.4 and 5.1).
Latvian: Nav ieteicama kombin cija ar AKE inhibitoriem (skat t apakšpunktus 4.4 un 5.1).
English: In clinically stable patients, therapy may be initiated as early as 12 hours after a myocardial infarction.
Latvian: Kl niski stabiliem pacientiem rst šanu var uzs kt jau 12 stundas p c miokarda infarkta.
English: What Diovan is and what it is used for Before you take Diovan How to take Diovan Possible side effects How to store Diovan Further information
Latvian: Kas ir Diovan un k dam nol kam to lieto Pirms Diovan lietošanas K lietot Diovan
English: Diovan belongs to a class of medicines known as angiotensin II receptor antagonist, which help to control high blood pressure.
Latvian: Diovan pieder z u grupai, kas paz stama k angiotenz na II receptoru antagonisti, un kas pal dz regul t augstu asinsspiedienu.
English: The average accumulation factor is about 1.7.
Latvian: Vid jais kumul cijas faktors ir apm ram 1,7.
English: This medicinal product is authorised in the Member States of the EEA under the following names: [To be completed nationally]
Latvian: Šis medic niskais produkts Eiropas ekonomisk s zonas (EEA) dal bvalst s ir re istr ts ar š diem nosaukumiem: [Aizpilda nacionli]
English: Valsartan may be used in patients treated with other post-myocardial infarction therapies, e.g. thrombolytics, acetylsalicylic acid, beta blockers, statins, and diuretics.
Latvian: Valsart nu var ordin t pacientiem, kuriem p rciesta miokarda infarkta gad jum tiek lietota cita medikamentoz terapija, t.i., trombol tiskie l dzek i, acetilsalicilsk be, beta-blokatori, stat ni un diur tikas.
English: AUC and Cmax values of valsartan are almost proportional with increasing dose over the clinical dosing range (40 to 160 mg twice a day).
Latvian: Valsart na AUC un Cmax v rt bas ir gandr z proporcion las devas palielin šanai kl nisko devu robež s (40 l dz 160 mg divas reizes dien ).
English: When angiotensin II antagonists are administered simultaneously with NSAIDs, attenuation of the antihypertensive effect may occur.
Latvian: Ja angiotenz na II antagonisti tiek lietoti kop ar NPL, antihipertens v iedarb ba var samazin ties.
English: Adult patients with heart failure: Treatment starts generally with 40 mg twice daily.
Latvian: Pieaugušie pacienti ar sirds mazsp ju: rst šanu parasti s k ar 40 mg devu divas reizes dien .
English: There was no difference between valsartan and captopril in all-cause mortality based on age, gender, race, baseline therapies or underlying disease.
Latvian: Netika konstat tas visu mirst bas c lo u atš ir bas, kas saist tas ar vecumu, dzimumu, rasi, pamatterapiju vai pamatslim bu.
English: All cause mortality was similar (p=NS) in the valsartan (19.7%) and placebo (19.4%) groups.
Latvian: Visi mirst bas c lo i valsart na grup (19,7%) un placebo grup (19,4%) bija l dz gi (p=NS).
English: Take Diovan at about the same time each day.
Latvian: Diovan ieteicams lietot vien un tai paš laik katru dienu.
English: These side effects may occur with certain frequencies, which are defined as follows: very common: affects more than 1 user in 10 common: affects 1 to 10 users in 100 uncommon: affects 1 to 10 users in 1,000 rare: affects 1 to 10 users in 10,000 very rare: affects less than 1 user in 10,000 not known: frequency cannot be estimated from the available data.
Latvian: Š m blakuspar d b m var b t noteikt biežums, kas defin ts š di: oti bieži: att st s maz k k 1 pacientam no katriem 10 pacientiem bieži: att st s 1 l dz 10 pacientiem no katriem 100 pacientiem ret k: att st s 1 l dz 10 pacientiem no katriem 1 000 pacientiem reti: att st s 1 l dz 10 pacientiem no katriem 10 000 pacientiem oti reti: att st s maz k k 1 pacientam no katriem 10 000 pacientiem nav zin mi: nevar noteikt p c pieejamiem datiem.
English: Following oral administration of valsartan alone, peak plasma concentrations of valsartan are reached in 24 hours with tablets and 1-2 hours with solution formulation.
Latvian: P c iekš gas viena paša valsart na lietošanas, maksim l valsart na plazmas koncentr cija tiek sasniegta 2-4 stund s, lietojot tabletes, un 1-2 stund s, lietojot š dumu iekš gai lietošanai.
English: The recommended starting dose of Diovan is 40 mg twice daily.
Latvian: Diovan ieteicam s kuma deva ir 40 mg divas reizes dien .
English: Weight
Latvian: Stiprums
English: Discontinuations due to various types of renal dysfunction occurred in 1.1% of valsartan-treated patients, 1.3% in valsartan+captopril patients, and 0.8% of captopril patients.
Latvian: Z u lietošanas p rtraukšana daž da veida nieru disfunkciju d bija nepieciešama 1,1% ar valsart nu rst tajiem pacientiem, 1,3% ar valsart nu+kaptoprilu rst tajiem pacientiem un 0,8% ar kaptoprilu rst tajiem pacientiem.
English: Adverse reactions are ranked by frequency, the most frequent first, using the following convention: very common ( 1/10); common ( 1/100 to <1/10); uncommon ( 1/1,000 to <1/100); rare ( 1/10,000 to <1/1,000) very rare (<1/10,000), including isolated reports.
Latvian: Nev lam s blakuspar d bas apkopotas biežuma mazin šan s sec b , biež k s nor dot vispirms, š d veid : oti bieži (1/10), bieži (1/100 l dz <1/10), ret k (1/1 000 l dz <1/100), reti (1/10 000 l dz <1/1 000), oti reti (<1/10 000), ieskaitot atseviš us zi ojumus.
English: Treatment of symptomatic heart failure in adult patients when Angiotensin Converting Enzyme (ACE) inhibitors cannot be used, or as add-on therapy to ACE inhibitors when beta blockers cannot be used (see sections 4.4 and 5.1).
Latvian: Simptom tiskas sirds mazsp jas rst šana pieaugušiem pacientiem, kad nav pielietojami angiotenz na konvert još enz ma (AKE) inhibitori, vai k papildin jums rst šanai ar AKE inhibitoriem, kad nevar izmantot beta-blokatorus (skat t apakšpunktus 4.4 un 5.1).
English: There was no difference in all-cause mortality, cardiovascular mortality or morbidity when beta blockers were administered together with the combination of valsartan + captopril, valsartan alone, or captopril alone.
Latvian: Netika konstat tas atš ir bas visu c lo u izrais tas mirst bas vai kardiovaskul ras mirst bas, vai saslimšanas gadjum, kad kombincij ar valsartnu + kaptoprilu, valsartnu vienu pašu vai kaptoprilu vienu pašu, tika ordin ti beta-blokatori.
English: Daily oral dosing of neonatal/juvenile rats (from a postnatal day 7 to postnatal day 70) with valsartan at doses as low as 1 mg/kg/day (about 10-35% of the maximum recommended paediatric dose of 4 mg/kg/day on systemic exposure basis) produced persistent, irreversible kidney damage.
Latvian: Jaundzimuš m/jaun m žurk m (no 7 l dz 70 dienai p c dzimšanas) valsart na 1 mg/kg/dien devas (kas ir aptuveni 10-35% no maksim li ieteicam s devas b rniem 4 mg/kg/dien pamatojoties uz sist misko iedarb bu) iekš ga lietošana izrais ja past v gus un neatgriezeniskus nieru boj jumus.
English: There is currently no experience on the safe use in patients with a creatinine clearance <10 ml/min and patients undergoing dialysis, therefore valsartan should be used with caution in these patients (see sections 4.2 and
Latvian: Pašlaik nav pieredzes par drošu lietošanu pacientiem ar kreatin na kl rensu <10 ml/min un pacientiem, kuri p rcietuši dial zi, t d j di valsart nu šiem pacientiem nepieciešams lietot piesardz gi (skat t apakšpunktus 4.2 un 4.4).
English: Diovan is used when a group of medicines called Angiotensin Converting Enzyme (ACE) inhibitors (a medication to treat heart failure) cannot be used or it may be used in addition to ACE inhibitors when beta blockers (another medication to treat heart failure) cannot be used.
Latvian: Diovan lieto tad, kad nevar tikt izmantota z u grupa - angiotenz nu konvert još faktora (AKE) inhibitori (z les sirds mazsp jas rst šanai) vai to var lietot papildus AKE inhibitoriem, kad nevar lietot beta blokatorus (citas z les sirds mazsp jas rst šanai).
English: Provas 40 mg 40 mg
Latvian: Provas 40 mg
English: The combination of captopril and valsartan has shown no additional clinical benefit, instead the risk for adverse events increased compared to treatment with the respective therapies (see sections 4.2 and 5.1).
Latvian: Kaptoprila un valsartna kombincija nav pierdjusi papildu klnisko ieguvumu, t viet ir palielinjies nev lamo blakuspardbu risks, saldzinot ar atbilstošo rst šanu (skatt apakšpunktus 4.2 un 5.1).
English: The VALsartan In Acute myocardial iNfarcTion trial (VALIANT) was a randomised, controlled, multinational, double-blind study in 14,703 patients with acute myocardial infarction and signs, symptoms or radiological evidence of congestive heart failure and/or evidence of left ventricular systolic dysfunction (manifested as an ejection fraction 40% by radionuclide ventriculography or 35% by echocardiography or ventricular contrast angiography).
Latvian: Tika veikti p t jumi ar valsart nu p c ak ta miokarda infarkta (The VALsartan In Acute myocardial iNfarcTion trial-VALIANT), kur kontrol tos, multinacionlos, dubultmask tos, nejaušintos p tjumos tika iekauti 14 703 pacienti ar ak tu miokarda infarktu un radioloiski diagnostic tu sastr guma sirds mazsp ju vai t s paz m m, simptomiem un/vai pier d jumiem par kreis kambara sistolisko disfunkciju (kas manifest jas k izsviedes frakcija 40%, nosakot ar radionukle du ventrikulogr fiju, vai 35%, nosakot ar ehokardiogr fiju vai ventrikul ro kontrastangiogr fiju).
English: Adult patients after a recent heart attack: After a heart attack the treatment is generally started as early as after 12 hours, usually at a low dose of 20 mg twice daily.
Latvian: Pieaugušie pacienti p c nesen p rciesta miokarda infarkta: P c p rciesta miokarda infarkta rst šanu parasti uzs k jau p c 12 stund m, parasti lietojot maz ko devu-pa 20 mg divas reizes dien . J
English: • elevation of liver function values (which can indicate liver damage) including an increase of bilirubin in the blood (which can trigger yellow skin and eyes in severe cases)
Latvian: • aknu funkcion lo r d t ju palielin šan s (kas var nor d t uz aknu boj jumiem), tostarp bilirub na l me a palielin šan s asin s (kas smagos gad jumos var izrais t das un acu dzelti)
English: Diovan and associated names (see Annex I) 40 mg film-coated tablets Diovan and associated names (see Annex I) 80 mg film-coated tablets Diovan and associated names (see Annex I) 160 mg film-coated tablets Diovan and associated names (see Annex I) 320 mg film-coated tablets [See Annex I - To be completed nationally]
Latvian: Diovan un citi nosaukumi (skat t Pielikumu I) 40 mg apvalkot s tabletes Diovan un citi nosaukumi (skat t Pielikumu I) 80 mg apvalkot s tabletes Diovan un citi nosaukumi (skat t Pielikumu I) 160 mg apvalkot s tabletes Diovan un citi nosaukumi (skat t Pielikumu I) 320 mg apvalkot s tabletes [Skat t Pielikumu I - aizpilda nacion li]
English: Results appearing to favour placebo (composite mortality and morbidity was 21.9% in placebo vs. 25.4% in valsartan group) were observed for those patients receiving the triple combination of an ACE inhibitor, a beta blocker and valsartan.
Latvian: Tom r riska samazin jums par labu placebo (kombin t saslimst ba un mirst ba 21,9% placebo grup pret 25,4% valsart na grup ) tika nov rota tiem pacientiem, kuriem tika lietota beta-blokatoru, AKE inhibitoru un valsart na tr sk rša kombin cija.
English: Provas 80 mg 80 mg
Latvian: Provas 80 mg
English: Method of administration Diovan may be taken independently of a meal and should be administered with water.
Latvian: Lietošanas veids Diovan var lietot neatkargi no dienreiz m, un to nepieciešams lietot, uzdzerot deni.
English: In this subgroup all-cause mortality was significantly reduced with valsartan compared to placebo by 33% (95% CI: -6% to 58%) (17.3% valsartan vs. 27.1% placebo) and the composite mortality and morbidity risk was significantly reduced by 44% (24.9% valsartan vs. 42.5% placebo).
Latvian: Šaj , valsart na apakšgrup visu c lo u izrais t letalit te tika b tiski samazin ta, sal dzinot ar placebo par 33% (95% CI: -6% l dz 58%) (17,3% valsart ns pret 27,1% placebo) un kombin tais saslimst bas un letalit tes risks tika iev rojami samazin ts par 44% (24,9% valsart ns pret 42,5% placebo).
English: Treatment of clinically stable adult patients with symptomatic heart failure or asymptomatic left ventricular systolic dysfunction after a recent (12 hours-10 days) myocardial infarction (see sections 4.4 and 5.1).
Latvian: Kl niski stabilu pieaugušo pacientu ar simptom tisku sirds mazsp ju vai asimptom tisku sirds kreis kambara sistolisko disfunkciju p c nesen p rciesta (12 stundas-10 dienas) miokarda infarkta rst šana (skat t apakšpunktus 4.4 un 5.1).
English: Diovan and associated names (see Annex I) 40 mg film-coated tablets Diovan and associated names (see Annex I) 80 mg film-coated tablets Diovan and associated names (see Annex I) 160 mg film-coated tablets Diovan and associated names (see Annex I) 320 mg film-coated tablets [See Annex I -To be completed nationally] Valsartan
Latvian: Diovan un citi nosaukumi (skat t Pielikumu I) 40 mg apvalkot s tabletes Diovan un citi nosaukumi (skat t Pielikumu I) 80 mg apvalkot s tabletes Diovan un citi nosaukumi (skat t Pielikumu I) 160 mg apvalkot s tabletes Diovan un citi nosaukumi (skat t Pielikumu I) 320 mg apvalkot s tabletes [Skat t Pielikumu I - aizpilda nacion li] Valsartanum
English: Regarding renal function, doubling of serum creatinine was observed in 4.2% of valsartan-treated patients, 4.8% of valsartan+captopril-treated patients, and 3.4% of captopril-treated patients.
Latvian: Saist b ar nieru funkciju, 4,2% ar valsart nu rst tajiem pacientiem, 4,8% ar valsart nu+kaptoprilu rst tajiem pacientiem un 3,4% ar kaptoprilu rst tajiem pacientiem tika konstat ts divk ršs seruma kreatin na l menis.
English: Like all medicines, Diovan can cause side effects, although not everybody gets them.
Latvian: T pat k citas z les, Diovan var izrais t blakuspar d bas, kaut ar ne visiem t s izpaužas.
English: Recent myocardial infarction
Latvian: Nesen p rciests miokarda infarkts
English: Non-steroidal anti-inflammatory medicines (NSAIDs), including selective COX-2 inhibitors, acetylsalicylic acid >3 g/day), and non-selective NSAIDs
Latvian: selekt viem COX-2 inhibitoriem, acetilsalicilsk bi >3 g/dien un neselekt vas darb bas NPL.
English: When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).
Latvian: Diagnostic jot gr tniecbu, nepieciešams nekav joties prtraukt rst šanu ar AIIRA un nepieciešam bas gad jum uzs kt alternat vu rst šanu (skat t apakšpunktus 4.3 un 4.6).
English: The target maximum dose is 160 mg twice daily.
Latvian: Maksim l deva atbilst 160 mg divas reizes dien .
English: • [Storage conditions statements - To be completed nationally]
Latvian: • [Uzglab šanas apst k i - aizpilda nacion li]
English: Rixil 320 mg 320 mg
Latvian: Rixil 320 mg
English: Rua do Centro Empresarial, Edificio 8 Quinta da Beloura
Latvian: Quinta da Beloura
English: Provas 320 mg 320 mg
Latvian: Provas 320 mg